Lipid News

Dysregulation of a lipid transfer protein linked to brain disorders

Kentaro Hanada
By Kentaro Hanada
April 12, 2022

Advanced studies of human genetics are a big wave in the medical sciences. Collaborative teams of clinical geneticists and bioinformaticians are surfing this wave, rapidly discovering genomic variations associated with specific human disorders. This trend is providing scientific bases for personalized medicines but also new, important questions linked to the basic biochemistry field.

Ceramide transport protein, or CERT, moves the waxy lipids known as ceramides in cells for the synthesis of sphingomyelin, a membrane lipid that is ubiquitous in mammalian cells. In 2007, researchers found that CERT is functionally repressed by multiple phosphorylations of a serine-repeat motif, or SRM, in CERT. At the time, scientists regarded this finding as pure biochemistry of a protein.

However, a decade later, large-scale human genetic studies on intellectual disabilities and mental development disorders, or ID/MD, showed that missense mutations in or near the CERT SRM-encoding regions are associated with a type of autosomal dominant hereditary ID/MD. The dominant inheritance was in line with a prediction from the previous biochemical study that loss of hyperphosphorylation of the SRM renders CERT abnormally active.

Our recent collaborative study confirmed this prediction by demonstrating that substitution of a serine residue in the SRM with other residues similar to variants found in ID/MD patients results in dysregulation of CERT in cultured cells. Nonetheless, several ID/MD-associated missense mutations that occurred in the CERT gene CERT1 also are mapped outside the SRM. This riddle was answered by another recent study showing that a non-SRM variant also compromises the SRM hyperphosphorylation, thereby abnormally activating CERT.

Moreover, cell biological analysis showed that abnormally activated CERT mutants exhibit an aberrant punctate distribution in cells, suggesting that the subcellular distribution pattern is applicable as a diagnostic tool to assess whether a CERT1 variant is an abnormally activated type that may cause ID/MD, although the precise identity of the puncta structure remains undetermined.

Advanced  human genetics studies have shown that missense mutations in the CERT1 gene encoding the ceramide <em>transport protein </em>CERT are associated with certain intellectual  disabilities and mental development disorders. Recent studies in the Hanada lab  showed that ID/MD-associated CERT variants are defective in the serine-repeat  motif phosphorylation-dependent repression. In this diagram, for simplicity, CERT  is illustrated as a monomer, although it forms oligomers in cells.
Kentaro Hanada
Advanced human genetics studies have shown that missense mutations in the CERT1 gene encoding the ceramide transport protein CERT are associated with certain intellectual disabilities and mental development disorders. Recent studies in the Hanada lab showed that ID/MD-associated CERT variants are defective in the serine-repeat motif phosphorylation-dependent repression. In this diagram, for simplicity, CERT is illustrated as a monomer, although it forms oligomers in cells.

Want more lipid research news?

Check out Lipid Trends, a curated collection of hot picks from the world of lipid research, brought to you by LIPID MAPS.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Kentaro Hanada
Kentaro Hanada

Kentaro Hanada is a senior researcher in the quality assurance, radiation safety and information management department of the National Institute of Infectious Diseases in Japan, where he is also former director of the biochemistry and cell biology department and an emeritus officer.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

A biological camera: How AI is transforming retinal imaging
Feature

A biological camera: How AI is transforming retinal imaging

Oct. 15, 2025

AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
Essay

AI in the lab: The power of smarter questions

Oct. 14, 2025

An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Feature

Training AI to uncover novel antimicrobials

Oct. 9, 2025

Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.

AI-designed biomarker improves malaria diagnostics
Journal News

AI-designed biomarker improves malaria diagnostics

Oct. 8, 2025

Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Matrix metalloproteinase inhibitor reduces cancer invasion
Journal News

Matrix metalloproteinase inhibitor reduces cancer invasion

Oct. 8, 2025

Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.

Antibiotic sensor directly binds drug in resistant bacteria
Journal News

Antibiotic sensor directly binds drug in resistant bacteria

Oct. 8, 2025

Researchers at Drexel University uncover how the vancomycin-resistant bacterial sensor binds to the antibiotic, offering insights to guide inhibitor design that restores antibiotic effectiveness against hospital-acquired infections.